Breet NJ - Search Results

1

Vigorous exercise as a triggering mechanism for late stent thrombosis: A description of three cases.

Zwart B, Van Kerkvoorde TC, van Werkum JW, Breet NJ, Ten Berg JM, Van 't Hof AW. Zwart B, et al. Among authors: breet nj. Platelets. 2010;21(1):72-6. doi: 10.3109/09537100903388367. Platelets. 2010. PMID: 19929240

2

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Breet NJ, et al. JAMA. 2010 Feb 24;303(8):754-62. doi: 10.1001/jama.2010.181. JAMA. 2010. PMID: 20179285 Clinical Trial.

3

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.

Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, Ruven HJ, Klungel OH, de Boer A, Deneer VH. Harmsze AM, et al. Among authors: breet nj. Thromb Haemost. 2010 May;103(5):920-5. doi: 10.1160/TH09-08-0516. Epub 2010 Mar 29. Thromb Haemost. 2010. PMID: 20352154

4

The Cone-and-Plate(let) analyzer is not suitable to monitor clopidogrel therapy: a comparison with the flowcytometric VASP assay and optical aggregometry.

van Werkum JW, Bouman HJ, Breet NJ, ten Berg JM, Hackeng CM. van Werkum JW, et al. Among authors: breet nj. Thromb Res. 2010 Jul;126(1):44-9. doi: 10.1016/j.thromres.2010.03.008. Epub 2010 May 8. Thromb Res. 2010. PMID: 20452655

5

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.

Harmsze AM, van Werkum JW, Ten Berg JM, Zwart B, Bouman HJ, Breet NJ, van 't Hof AW, Ruven HJ, Hackeng CM, Klungel OH, de Boer A, Deneer VH. Harmsze AM, et al. Among authors: breet nj. Eur Heart J. 2010 Dec;31(24):3046-53. doi: 10.1093/eurheartj/ehq321. Epub 2010 Sep 10. Eur Heart J. 2010. PMID: 20833683

6

High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, ten Berg JM. Breet NJ, et al. Heart. 2011 Jun;97(12):983-90. doi: 10.1136/hrt.2010.220491. Epub 2011 Apr 8. Heart. 2011. PMID: 21478385 Clinical Trial.

7

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM. Bouman HJ, et al. Among authors: breet nj. Heart. 2011 Aug;97(15):1239-44. doi: 10.1136/hrt.2010.220509. Epub 2011 May 31. Heart. 2011. PMID: 21628721 Clinical Trial.

8

The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Hackeng CM, ten Berg JM. Breet NJ, et al. Thromb Haemost. 2011 Aug;106(2):331-6. doi: 10.1160/TH10-08-0528. Epub 2011 Jun 28. Thromb Haemost. 2011. PMID: 21713320

9

The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.

Hermanides RS, van Werkum JW, Ottervanger JP, Breet NJ, Gosselink AT, van Houwelingen KG, Dambrink JH, Hamm C, ten Berg JM, van 't Hof AW; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Hermanides RS, et al. Among authors: breet nj. Catheter Cardiovasc Interv. 2012 May 1;79(6):956-64. doi: 10.1002/ccd.23165. Epub 2011 Dec 12. Catheter Cardiovasc Interv. 2012. PMID: 22162050 Clinical Trial.

10

The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting.

Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, Breet NJ, Ten Berg JM, Klungel OH, de Boer A, Deneer VH. Harmsze AM, et al. Among authors: breet nj. Pharmacogenet Genomics. 2012 Mar;22(3):169-75. doi: 10.1097/FPC.0b013e32834ff6e3. Pharmacogenet Genomics. 2012. PMID: 22228204

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page